Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Roche, Catalent
Roche comes out against allowing takeover of drug manufacturer Catalent
The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by Novo Nordisk's controlling shareholder, citing harm to industry peers.
Roche CEO says Novo's Catalent buyout 'could be a problem' for smaller drugmakers
The groups behind the letter alleged that Novo Nordisk’s plant purchases could hinder not only the Danish drugmaker’s chief commercial rival, Eli Lilly, but also companies like Viking Therapeutics, Pfizer, Roche and AstraZeneca, who are working on their own metabolic offerings.
Roche CEO says antitrust regulators should block Catalent sale to Novo Foundation
The CEO of Swiss pharmaceuticals behemoth Roche (OTCQX:RHHBY) said he believes antitrust regulators should not allow Novo Nordisk Foundation's to purchase Catalent (NYSE:CTLT). "It's not a problem for us,
2d
on MSN
Roche Bets Up to $1 Billion to Solve Gene Therapy’s Big Problem
Roche Holding AG is willing to pay more than $1 billion to solve one of the biggest challenges of gene therapy: delivery.The ...
FierceBiotech
1d
Roche bets up to $1B to expand Dyno gene therapy delivery pact
After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. | In a new deal potentially ...
BioSpace
1d
Roche Inks Potential $1B Gene Therapy Deal With Dyno, Eyes Neurological Diseases
With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy ...
FiercePharma
2d
Roche's Vabysmo will rise above Eylea biosim threat, exec says, as DMD gene therapy Elevidys delivers sales surprise
By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...
FierceBiotech
3d
Roche culls cough candidate, pivots KRAS program after revaluing entire pipeline
Roche’s chronic cough program has sputtered to a halt. The drugmaker, which axed the program after the drug candidate ...
3d
Roche CEO Says More People Have Mpox in Europe Than Has Been Reported
FRANKFURT (Reuters) - The CEO of Roche said more cases of mpox infection have likely occurred in Europe than previously ...
1d
Dyno signs second Roche deal worth over $1B
George Church-founded Dyno Therapeutics Inc. is adding to its list of pharma deals by signing a second research collaboration ...
3d
on MSN
Roche reaffirms 2024 outlook after Q3 beat
Roche Holding (RHHBF) reaffirms full-year sales and earnings outlook after its Q3 results exceeded Street forecasts. Read ...
GEN
1d
Roche, Dyno Launch $1B+ AAV Gene Therapy Vector Collaboration
Roche will use Dyno’s technology, through which Dyno applies AI and high-throughput in vivo data collection to engineering ...
Opinion
15h
Opinion
Cheyenne Roche: What makes a city memorable
This summer, I went to 36 independently-owned bookstores across the state of Iowa. From big cities like Des Moines and ...
3d
on MSN
Roche Confirms Profit Forecast as Sales Beat Estimates
Roche said it would increase its dividend after its hemophilia injection Hemlibra and multiple sclerosis treatment Ocrevus ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Catalent
Dyno
Food and Drug Administration
Europe
mpox
Feedback